Original Publication Date: 1 June, 2014
Publication / Source: Immunotherapy
Authors: Taemin Oh, Michael E Ivan, Matthew Z Sun et al
Constitutive activation of the PI3K pathway has been implicated in glioblastoma (GBM) pathogenesis. Pharmacologic inhibition can both inhibit tumor survival and downregulate expression of programmed death ligand-1, a protein highly expressed on glioma cells that strongly contributes to cancer immunosuppression.